Cybin Company Presentation

Q3 2020 Q2 2021 Q1 2021 Q4 2020 Q2 2020 Q1 2020 Completed Completed Completed 16 Psychedelic Division Execution Timeline (1) (2) P r i v a t e & C o n f i d e n t i a l Pharmaceutical Psychedelic (Serenity) Delivery mechanism patents Synthetic psilocybin API source Psilocybin oral film manufacturer under contract Synthetic psilocybin API development (3) Oral film drug product clinical trial (1) Phase 2a and 2b MDD study completed with data (4) Transdermal patch development Transdermal delivery mechanism phase 1b trial (5) Microdose formulation Microdose safety & efficacy study (cognitive flexibility) (6) Pre and post psilocybin screening and protocol (1) Forward-looking statements are subject to various risks and assumptions. See “Cautionary Statement Regarding Forward-Looking Information” on page 2 of this presentation. (2) Based on a calendar year. Cybin financial year end is March 31 (3) Expected to provide psilocybin API for further studies, commercial oral film manufacturing and potential sales to research institutes. (4) Subject to receipt of all necessary regulatory approvals in Jamaica or other potential jurisdiction. (5) Subject to receipt of all necessary regulatory approvals in Jamaica or other potential jurisdiction. (6) Subject to receipt of all necessary regulatory approvals in Canada. Study will be performed by The Toronto Centre For Psychedelic Science. Q3 2021

RkJQdWJsaXNoZXIy NDMyMDk=